Go Back

AliveCor Granted Patent for Proactive Notification of Possible Heart Arrhythmias

December 12, 2017, Mountain View, CA

AliveCor, the leader in FDA-cleared personal electrocardiogram (EKG) technology, today announced issuance of a U.S. patent which covers the use of data collected from wearable devices as a means of assisting the diagnosis of heart arrhythmias, including those that may be asymptomatic.

U.S. Patent Number 9,839,363, entitled “Discordance Monitoring,” describes the analysis of heart rate data and activity data from wearable devices in order to trigger notifications for users to take an EKG when there is a difference between these two biometrics. Disagreement between a user's heart rate and activity level could be suggestive of any number of heart problems, including asymptomatic Atrial Fibrillation.

“Medical capture of asymptomatic heart arrhythmias is an ongoing challenge. Holter monitors, implantable recorders, and patches, all present various levels of inconvenience and discomfort. Our technology suggests a future in which detection of heart arrhythmias can be non-invasive, ultra-convenient, and highly reliable” said AliveCor Founder and Chief Medical Officer, Dr. David Albert.

AliveCor is presently in clinical trials to assess whether its SmartRhythm™ feature can be effective in the detection of a broad range of asymptomatic arrhythmias.

SmartRhythm, a component of AliveCor’s app for Apple Watch® and iPhone®, uses artificial intelligence in concert with inputs from Apple Watch’s heart rate and activity sensors to continuously evaluate the correlation between heart activity and physical activity. When SmartRhythm detects that heart rate and activity are out of sync, the device notifies users to capture an EKG with KardiaBand, or with KardiaMobile, AliveCor’s popular, portable EKG reader. For more information, see www.alivecor.com/smartrhythm.

About AliveCor
AliveCor, Inc. is pioneering the creation of FDA-cleared machine learning techniques to enable proactive heart care and is recognized around the world for transforming cardiac care. The FDA-cleared KardiaMobile™ is the most clinically validated mobile EKG solution on the market. It is recommended by leading cardiologists and used by people worldwide for accurate EKG recordings. KardiaMobile, and KardiaBand™, when paired with the Kardia app provide instant analysis for detecting atrial fibrillation (AF) and normal sinus rhythm in an EKG. Kardia is the first A.I. enabled platform to help clinicians manage patients for the early detection of atrial fibrillation, the most common cardiac arrhythmia and one that leads to a five times greater risk of stroke. KardiaBand is the first FDA-cleared medical device accessory for Apple Watch. AliveCor was recognized by Fast Company as one of 2017’s most innovative companies in health (#3). AliveCor is a privately-held company headquartered in Mountain View, Calif. For more information, please visit alivecor.com.

Most Recent

July 9, 2024

Introduction of AliveCor's revolutionary InstantQT® solution set to streamline ECG evaluation and enhance patient safety across Europe

Read More

June 25, 2024

AliveCor Announces Dual FDA Clearance of AI Technology That Delivers 35 Cardiac Determinations and First-of-its-Kind Kardia 12L ECG System

Read More

June 5, 2024

AliveCor’s AI-backed ECG Offerings Featured in New Film Series on Innovative Technologies Presented by the Consumer Technology Association

Read More

Let's transform cardiovascular care together

If you are an employer or payer looking for a comprehensive heart health enterprise solution, contact us.